| Objective:To investigate the treatment effects of inhaled furosemide to alleviate dyspnea in patientswith chronic heart failure.Methods:The study enrolled60patients with heart failure, recorded the subjects’ breathing rate,heart rate, mean arterial pressure, and plasma N-terminal brain natriuretic peptide (NT-proBNP), arterial blood gas analysis (including pH, PaCO2, PaO2, HCO3-and SaO2). In addition,subjects were asked to evaluate their degree of dyspnea (0=no dyspnea,10=most severedegree of dyspnea). Arterial blood gas was collected through the radial artery or femoralartery. In this randomised, single blind, placebo controlled trial, subjects were divided into acontrol treatment group and the control group, after conventional treatment in both groupswere4ml inhaled furosemide (20mg/2ml) once a day, or4ml saline, each once a day.Subjects’ mean arterial pressure, heart rate were recorded every15min for1h. Recordingrespiratory rate, arterial blood gas analysis, patients were asked to evaluate their degree ofdifficulty breathing again; NT-pro BNP was collected in the fifth day after the treatment.Results:1. There were significant changes in therespiratory rate of the two groups (P <0.05) afterthe first day ofadministration within one hour change. There were significantchangesinrespiratory rate in both groups at the end of the fifth day of administration (P<0.05). Therewere significant changes in dyspneascore after the first day of administration within one hourin both groups (P<0.05). There were significant changes in dyspneascore at the end of thefifth day of administration in both groups (P<0.05),but There were no significantchanges betweentwo groups (P>0.05).2.There were no significant changes in pH, PaCO2,SaO2after the treatment in experimental group (P>0.05), There were significant changes inPaO2, NT-pro BNP, dyspnea score, respiratory rate (P<0.05).2. There were no significant changes in PaCO2, pH, HCO3-, SaO2in the control group (P>0.05); there were significantchanges in respiratory rate, dyspnea score, NT-pro BNP (P<0.05).3. There were significantchanges in PaO2, dyspnea score, respiratory rate in the two groups changes after theexperiment (P<0.05), there were no significant changes in NT-pro BNP, pH, PaCO2, HCO3-,SaO2group (P>0.05).4. There were no significant changes in the average length of stay ofpatients (P>0.05).5. There were no significant changes in the mean arterial blood pressureand heart rate after the treatment.6.There were no significant changes in Na+, K+, Cl-, Ca2+concentration and creatinine.Conclusion:This study shows that inhaled furosemide for heart failure patients improve hypoxemiaand dyspnea have a role in the degree of reduction. To reduce cardiac wall tension, decreasedplasma levels of NT-pro BNP is not helpful. Study of inhaled furosemide serious adverseevent occurred, it has a good safety. |
PDF Full Text Request